Back to the main directory
EarningsReview / Equity
- 1Q25 first take: EBIT materially in line by BNP Paribas Exane
- Q1 2025 First take by BNP Paribas Exane
- Indian IT Services by HSBC
- A tidy conclusion: Cevian exits with a sale to Patria by BNP Paribas Exane
- 1Q25 First Take: A strong beat by BNP Paribas Exane
- LISI - Une publication totalement en ligne by MidCap Partners
- Groupe SEB - Une hirondelle ne fait vraiment pas le printemps, surtout chez Seb by MidCap Partners
- STEF - Conforme à nos attentes by MidCap Partners
- Vetoquinol - Vetoquinol allez à l’Essentiel by MidCap Partners
- OKwind - Résultats 2024 et CA T1 2025 by MidCap Partners
- Lectra - Résultats T1 by MidCap Partners
- Affluent Medical - FY24 by MidCap Partners
- US Spirits Data (NABCA, Mar'25): weak (again) by BNP Paribas Exane
- INVEST SECURITIES - TRANSGENE : Visibilité financière confirmée à avril 2025 - ACHAT, OC 1,7€ by Invest Securities
- DIA - Starting 2025 strongly as expected, we reiterate Buy by JB Capital Markets
- SAFRAN: VENTAS 1T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- INVEST SECURITIES - ALTEN : Discours ultra prudent, zéro momentum CT - ACHAT, OC 136€ vs 144€ by Invest Securities
- INVEST SECURITIES - ORYZON GENOMICS : €30M raised to support the mid term strategic plan - BUY, TARGET PRICE 10,9€ (vs 12,6€) by Invest Securities
- Q1-25 Pre-release by BNP Paribas Exane
- Tubacex - Uneventful 1Q25 print; outlook reiterated; Buy by JB Capital Markets
- MAPFRE: RDOS. 1T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- Groupe Guillin SA - Pressure on margins, as expected by MidCap Partners
- Affluent Medical - FY24 by MidCap Partners
- Groupe LDLC - Still decreasing by MidCap Partners
- Roche Bobois - A First Quarter Impacted by Delivery Delays by MidCap Partners
- AltynGold | FY24 results – a record year with more to come by Capital Access Group
- Q1 Revenue and EBITDA disappoint by BNP Paribas Exane
- Mapfre - 18% profit beat on better performance across the board by JB Capital Markets
- £300m SSCL contract extension by BNP Paribas Exane
- Q1 results: Solid EPS increase, tenant retention rate now normalised by BNP Paribas Exane
- Groupe Guillin SA - Pression sur la rentabilité, comme attendu by MidCap Partners
- Roche Bobois - Un premier trimestre impacté par des retards de livraison by MidCap Partners
- Groupe LDLC - Toujours dans le rouge by MidCap Partners
- Median Technologies - Rebond iCRO et perspectives Eyonis™ confirmés by MidCap Partners
- Kerlink - Situation financière parfaitement maîtrisée by MidCap Partners
- Ateme - CA T1 by MidCap Partners
- Pierre & Vacances SA - Croissance confirmée sur l’année by MidCap Partners
- INVEST SECURITIES - WORLDLINE : Toujours pas plus de visibilité - SOUS REVUE, OC SOUS REVUE by Invest Securities
- VINCI: VENTAS 1T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- INVEST SECURITIES - DASSAULT SYSTEMES : Momentum CT limité, perspectives MT/LT inchangées - ACHAT, OC 47€ vs 48€ by Invest Securities
- FQ1 Postview: Delivering across the board by BNP Paribas Exane
- AutoStore - Hold (Buy/NOK 15): Lack of visibility puts us on the sidelines by Nordea
- Pulp: Arauco reportedly cutting BHK prices $50/tonne (-8%) by BNP Paribas Exane
- CHINA POLITBURO, GREEN STEEL, STEEL CHINA, STEEL WEEKLY RECAP, VALE, FCX by BNP Paribas Exane
- Solid Q1 sales (+15 questions for management) by BNP Paribas Exane
- Small AUM miss, headwinds on balance sheet returns by BNP Paribas Exane
- Pierre & Vacances SA - Growth confirmed for FY by MidCap Partners
- Kerlink - Financial Position Perfectly Under Control ! by MidCap Partners
- STEF - In line with expectations by MidCap Partners
- Most Read Research - Week 18-24 April 2025 by BNP Paribas Exane